Costimulatory molecules and T-cell-B-cell interactions

Rheumatic Disease Clinics of North America

Volumn 30, Issue 1, 2004, Pages 175-191

  Crow, Mary K ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CD40 LIGAND MONOCLONAL ANTIBODY; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 4 1BB; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; ARTHRITIS; ATHEROSCLEROSIS; AUTOIMMUNITY; B LYMPHOCYTE; CELL INTERACTION; EFFECTOR CELL; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; REGULATORY MECHANISM; REVIEW; RHEUMATIC DISEASE; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TARGET CELL; THROMBOSIS; TRANSPLANTATION;

EID: 1242272832     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-857X(03)00111-X     Document Type: Review

References (89)

1. Edelman G.M. CAMs and Igs: cell adhesion and the evolutionary origins of immunity. Immunol Rev. 100:1987;11-45.
2. Gonzalo J.A., Delaney T., Corcoran J., Goodearl A., Gutierrez-Ramos J.C., Coyle A.J. Cutting edge: the related molecules CD28 and inducible costimulator deliver both unique and complementary signals required for optimal T cell activation. J Immunol. 166:2001;1-5.
3. Coyle A.J., Gutierrez-Ramos J.C. The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function. Nat Immunol. 2:2001;203-209.
4. Frauwirth K.A., Thompson C.B. Activation and inhibition of lymphocytes by costimulation. J Clin Invest. 109:2002;295-299.
5. Sharpe A.H., Freeman G.J. The B7-CD28 family. Nat Rev Immunol. 2:2002;116-126.
6. Shapiro L., Scherer P.E. The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr Biol. 8(6):1998;335-338.
7. Banchereau J., Bazan F., Blanchard D., Briere F., Galizzi J.P., van Kooten C.et al. The CD40 antigen and its ligand. Annu Rev Immunol. 12:1994;881-922.
8. Bretscher P., Cohn M. A theory of self-nonself discrimination. Science. 169:1970;1042-1049.
9. Bretscher P. The two-signal model of lymphocyte activation twenty-one years later. Immunol Today. 13:1992;74-76.
10. Crow M.K., Kunkel H.G. Human dendritic cells: major stimulators of the autologous and allogeneic mixed leucocyte reactions. Clin Exp Immunol. 49(2):1982;338-346.
11. Van Voorhis W.C., Valinsky J., Hoffman E., Luban J., Hair L.S., Steinman R.M. Relative efficacy of human monocytes and dendritic cells as accessory cells for T cell replication. J Exp Med. 158(1):1983;174-191.
12. Crow M.K., Kunkel H.G. Activated B lymphocytes: stimulators of an augmented autologous mixed leukocyte reaction. Cell Immunol. 90(2):1985;555-568.
13. Schwartz R.H. T cell anergy. Annu Rev Immunol. 21:2003;305-334.
14. Dabbagh K., Dahl M.E., Stepick-Biek P., Lewis D.B. Toll-like receptor 4 is required for optimal development of Th2 immune responses: role of dendritic cells. J Immunol. 168(9):2002;4524-4530.
15. Shlomchik M.J., Craft J.E., Mamula M.J. From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol. 1(2):2001;147-153.
16. + immunoregulatory T cells that control autoimmune diabetes. Immunity. 12:2000;431-440.
17. + T cells in severe rheumatoid arthritis. Arthritis Rheum. 40(6):1997;1106-1114.
18. Hutloff A., Dittrich A.M., Beier K.C., Eljaschewitsch B., Kraft R., Anagnostopoulos I.et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature. 397:1999;263-266.
19. Coyle A.J., Lehar S., Lloyd C., Tian J., Delaney T., Manning S.et al. The CD28-related molecule ICOS is required for effective T cell-dependent immune responses. Immunity. 13:2000;95-105.
20. Okazaki T., Iwai Y., Honjo T. New regulatory co-receptors: inducible co-stimulator and PD-1. Curr Opin Immunol. 14:2002;779-782.
21. + T cell responses by ICOS/B7h costimulation. J Immunol. 167:2001;132-139.
22. Linton P.-J., Bautista B., Biederman E., Bradley E.S., Harbertson J., Kondrack R.M.et al. Costimulation via OX40L expressed by B cells is sufficient to determine the extent of primary CD4 cell expansion and Th2 cytokine secretion in vivo. J Exp Med. 197:2003;875-883.
23. Futagawa T., Akiba H., Kodama T., Takeda K., Hosoda Y., Yagita H.et al. Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Int Immunol. 14(3):2002;275-286.
24. Feito M.J., Vaschetto R., Criado G., Sanchez A., Chiocchetti A., Jimenez-Perianez A.et al. Mechanisms of H4/ICOS costimulation: effects on proximal TCR signals and MAP kinase pathways. Eur J Immunol. 3:2003;204-214.
25. Acuto O., Mise-Omata S., Mangino G., Michel F. Molecular modifiers of T cell antigen receptor triggering threshold: the mechanism of CD28 costimulatory receptor. Immunol Rev. 192:2003;21-31.
26. Rudd C.E., Raab M. Independent CD28 signaling via VAV and SLP-76: a model for in trans costimulation. Immunol Rev. 192:2003;32-41.
27. Lindstein T., June C.H., Ledbetter J.A., Stella G., Thompson C.B. Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Science. 244(4902):1989;339-343.
28. de Boer M., Kasran A., Kwekkeboom J., Walter H., Vandenberghe P., Ceuppens J.L. Ligation of B7 with CD28/CTLA-4 on T cells results in CD40 ligand expression, interleukin-4 secretion and efficient help for antibody production by B cells. Eur J Immunol. 23(12):1993;3120-3125.
29. Smith K.M., Brewer J.M., Webb P., Coyle A.J., Gutierrez-Ramos C., Garside P. Inducible costimulatory molecule-B7-related protein 1 interactions are important for the clonal expansion and B cell helper functions of naïve, Th1, and Th2 T cells. J Immunol. 170:2003;2310-2315.
30. Pricop L., Redecha P., Teillaud J.L., Frey J., Fridman W.H., Sautes-Fridman C.et al. Differential modulation of stimulatory and inhibitory Fc gamma receptors on human monocytes by Th1 and Th2 cytokines. J Immunol. 166(1):2001;531-537.
31. Freeman G.J., Long A.J., Iwai Y., Bourque K., Chernova T., Nishimura H. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 192:2000;1027-1034.
32. Greenwald R.J., Oosterwegel M.A., van Der Woude D., Kubal A., Mandelbrot D.A., Boussiotis V.A.et al. CTLA-4 regulates cell cycle progression during a primary immune response. Eur J Immunol. 32:2002;366-373.
33. Greenwald R.J., Latchman Y.E., Sharpe A.H. Negative co-receptors on lymphocytes. Curr Opin Immunol. 14:2002;391-396.
34. Fallarino F., Grohmann U., Hwang K.W., Orabona C., Vacca C., Bianchi R. et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol. 4:2003;1206-1212.
35. Wang S., Bajorath J., Flies D.B., Dong H., Honjo T., Chen L. Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction. J Exp Med. 197:2003;1083-1091.
36. Collins A.V., Brodie D.W., Gilbert R.J., Iaboni A., Manso-Sancho R., Walse B.et al. The interaction properties of costimulatory molecules revisited. Immunity. 17(2):2002;201-210.
37. McAdam A.J., Greenwald R.J., Levin M.A., Chernova T., Malenkovich N., Ling V.et al. ICOS is critical for CD40-mediated antibody class switching. Nature. 409:2001;102-105.
38. Liszewski M.K., Farries T.C., Lublin D.M., Rooney I.A., Atkinson J.P. Control of the complement system. Adv Immunol. 61:1996;201-283.
39. Mackay F., Kalled S.L. TNF ligands and receptors in autoimmunity: an update. Curr Opin Immunol. 14(6):2002;783-790.
40. + T cells that induces contact dependent B cell differentiation. J Exp Med. 175:1992;1091-1101.
41. Hollenbaugh D., Grosmire I., Kullas C., Chalupny N., Braesch-Andersen S., Noelle R.et al. The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell costimulatory activity. EMBO J. 11:1992;4314-4321.
42. Spriggs M.K., Armitage R.J., Strockbine L., Clifford K.N., Macduff B.M., Sato T.A.et al. Recombinant human CD40 ligand stimulates B cell proliferation and immunoglobulin E secretion. J Exp Med. 176:1992;1543-1550.
43. Allen R.C., Armitage R.J., Conley M.E., Rosenblatt H., Jenkins N.A., Copeland N.G.et al. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science. 259:1993;990-993.
44. Korthauer U., Graf D., Mages H.W., Briere F., Padayachee M., Malcolm S. et al. Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature. 361:1993;539-541.
45. DeSanto J.P., Bonnefoy J.Y., Gauchat J.F., Fischer A., de Saint Basile G. CD40 ligand mutations in X-linked immunodeficiency with hyper-IgM. Nature. 361:1993;541-543.
46. Aruffo A., Farrington M., Hollenbaugh D., Li X., Milatovich A., Nonoyama S.et al. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell. 72:1993;291-300.
47. Ramesh N., Fuleihan R., Ramesh V., Lederman S., Yellin M.J., Sharma S.et al. Deletions in the ligand for CD40 in X-linked immunoglobulin deficiency with normal or elevated IgM (HIGMX-1). Int Immunol. 5:1993;769-773.
48. Shapira S.K., Vercelli D., Jabara H.H., Fu S.M., Geha R.S. Molecular analysis of the induction of immunoglobulin E synthesis in human B cells by interleukin 4 and engagement of CD40 antigen. J Exp Med. 175:1992;289-292.
49. Splawski J.B., Fu S.M., Lipsky P.E. Immunoregulatory role of CD40 in human B cell differentiation. J Immunol. 150:1993;1276-1285.
50. Grabstein K.H., Maliszexshi C.R., Shanebeck K., Sato T.A., Spriggs M.K., Fanslow W.C.et al. The regulation of T cell-dependent antibody formation in vitro by CD40 ligand and IL-2. J Immunol. 150:1993;3141-3147.
51. Nonoyama S., Hollenbaugh D., Aruffo A., Ledbetter J.A., Ochs H.D. B cell activation via CD40 is required for specific antibody production by antigen-stimulated human B cells. J Exp Med. 178:1993;1097-1102.
52. Lederman S., Yellin M.J., Cleary A.M., Pernis A., Inghirami G., Cohn L.E.et al. T-BAM/CD40-L on helper T lymphocytes augments lymphokine-induced B cell Ig isotype switch recombination and rescues B cells from programmed cell death. J Immunol. 152:1994;2163-2171.
53. Klaus S.L., Pinchuk L.M., Ochs H.D., Law C.-L., Fanslow W.C., Armitage R.J.et al. Costimulation through CD28 enhances T cell-dependent B cell activation via CD40-CD40L interaction. J Immunol. 152:1994;5643-5652.
54. Schattner E., Elkon K.B., Tumang J., Crow M.K., Friedman S.M. Signaling through the B cell antigen CD40 induces Apo-1 expression on human B lymphocytes and facilitates malignant B cell death. J Exp Med. 182:1995;1557-1565.
55. Caux C., Massacrier C., Vanbervliet B., Dubois B., Van Kooten C., Durand I. Activation of human dendritic cells through CD40 cross-linking. J Exp Med. 180(4):1994;1263-1272.
56. Alderson M.R., Armitage R.J., Tough T.W., Strockbine L., Fanslow W.C., Spirggs M.K. CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40. J Exp Med. 178:1993;669-674.
57. Kobayashi N., Nagumo H., Agematsu K. IL-10 enhances B-cell IgE synthesis by promoting differentiation into plasma cells, a process that is inhibited by CD27/CD70 interaction. Clin Exp Immunol. 129(3):2002;446-452.
58. Kumar-Sinha C., Varambally S., Sreekumar A., Chinnaiyan A.M. Molecular cross-talk between the TRAIL and interferon signaling pathways. J Biol Chem. 277(1):2002;575-585.
59. + B cells. J Immunol. 165(2):2000;786-794.
60. Pollard K.M., Hultman P., Kono D.H. Using single-gene deletions to identify checkpoints in the progression of systemic autoimmunity. Ann N Y Acad Sci. 987:2003;236-239.
61. Castigli E., Alt F.W., Davidson L., Bottaro A., Mizoguchi E., Bhan A.K. et al. CD40-deficient mice generated by recombination-activating gene-2-deficient blastocyst complementation. Proc Natl Acad Sci USA. 91(25):1994;12135-12139.
62. Tafuri A., Shahinian A., Bladt F., Yoshinaga S.K., Jordana M., Wakeham A.et al. ICOS is essential for effective T-helper-cell responses. Nature. 409(6816):2001;105-109.
63. Dong C., Juedes A.E., Temann U.A., Shresta S., Allison J.P., Ruddle N.H.et al. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature. 409(6816):2001;97-101.
64. Tivol E.A., Borriello F., Schweitzer A.N., Lynch W.P., Bluestone J.A., Sharpe A.H. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 3:1995;541-547.
65. Waterhouse P., Penninger J.M., Timms E., Wakeham A., Shahinian A., Lee K.P.et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science. 270:1995;985-988.
66. Nishimura H., Nose M., Hiai H., Minato N., Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 11:1999;141-151.
67. Nishimura H., Okazaki T., Tanaka Y., Nakatani K., Hara M., Matsumori A. et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 291:2001;319-322.
68. Mehling A., Loser K., Varga G., Metze D., Luger T.A., Schwarz T.et al. Overexpression of CD40 ligand in murine epidermis results in chronic skin inflammation and systemic autoimmunity. J Exp Med. 194(5):2001;615-628.
69. Chu J.L., Drappa J., Parnassa A., Elkon K.B. The defect in Fas mRNA expression in MRL/lpr mice is associated with insertion of the retrotransposon, ETn. J Exp Med. 178(2):1993;723-730.
70. Hilliard B., Wilmen A., Seidel C., Liu T.S., Goke R., Chen Y. Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitis. J Immunol. 166(2):2001;1314-1319.
71. Koshy M., Berger D., Crow M.K. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest. 98(3):1996;826-837.
72. Desai-Mehta A., Lu L., Ramsey-Goldman R., Datta S.K. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest. 97(9):1996;2063-2073.
73. Mohan C., Shi Y., Laman J.D., Datta S.K. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol. 154(3):1995;1470-1480.
74. Vakkalanka R.K., Woo C., Kirou K.A., Koshy M., Berger D., Crow M.K. Elevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera. Arthritis Rheum. 42(5):1999;871-881.
75. Kato K., Santana-Sahagun E., Rassenti L.Z., Weisman M.H., Tamura N., Kobayashi S.et al. The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J Clin Invest. 104(7):1999;947-955.
76. Bijl M., Horst G., Limburg P.C., Kallenberg C.G. Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus. Ann Rheum Dis. 60(5):2001;523-526.
77. Prokunina L., Castillejo-Lopez C., Oberg F., Gunnarsson I., Berg L., Magnusson V.et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet. 32(4):2002;666-669.
78. Pullmann R. Jr., Lukac J., Skerenova M., Rovensky J., Hybenova J., Melus V.et al. Cytotoxic T lymphocyte antigen 4 (CTLA-4) dimorphism in patients with systemic lupus erythematosus. Clin Exp Rheumatol. 17(6):1999;725-729.
79. Hudson L.L., Rocca K., Song Y.W., Pandey J.P. CTLA-4 gene polymorphisms in systemic lupus erythematosus: a highly significant association with a determinant in the promoter region. Hum Genet. 111(4-5):2002;452-455.
80. Daikh D.I., Finck B.K., Linsley P.S., Hollenbaugh D., Wofsy D. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J Immunol. 159(7):1997;3104-3108.
81. Emery P. The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis. Expert Opin Investig Drugs. 12(4):2003;673-681.
82. Wang X., Huang W., Mihara M., Sinha J., Davidson A. Mechanism of action of combined short-term CTLA4Ig and anti-CD40 ligand in murine systemic lupus erythematosus. J Immunol. 168(4):2002;2046-2053.
83. Knoerzer D.B., Karr R.W., Schwartz B.D., Mengle-Gaw L.J. Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig. J Clin Invest. 96(2):1995;987-993.
84. + T lymphocytes. J Clin Invest. 111:2003;1133-1145.
85. Kosuge H., Suzuki J., Gotoh R., Koga N., Ito H., Isobe M.et al. Induction of immunologic tolerance to cardiac allograft by simultaneous blockade of inducible co-stimulator and cytotoxic T-lymphocyte antigen 4 pathway. Transplantation. 75(8):2003;1374-1379.
86. Foell J., Strahotin S., O'Neil S.P., McCausland M.M., Suwyn C., Haber M.et al. CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB x NZW F(1) mice. J Clin Invest. 111(10):2003;1505-1518.
87. Kalled S.L., Cutler A.H., Datta S.K., Thomas D.W. Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function. J Immunol. 160(5):1998;2158-2165.
88. Kalunian K.C., Davis J.C. Jr., Merrill J.T., Totoritis M.C., Wofsy D. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46(12):2002;3251-3258.
89. Huang W., Sinha J., Newman J., Reddy B., Budhai L., Furie R.et al. The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis Rheum. 46(6):2002;1554-1562.